296 assets in Myelodysplastic Syndrome

Therapeutic assets addressing Myelodysplastic Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
prt2527 Myelodysplastic Syndrome	Prelude Therapeutics	P1	CC (47)
Apg 115 Myelodysplastic Syndrome	Ascentage Pharma Group Inc.	P1/2	CC (46)
Petadeferitrin Myelodysplastic Syndrome	Pharmacosmos A/S	P2	CC (46)
Bsb-1001 Myelodysplastic Syndrome	BlueSphere Bio, Inc	P1/2	CC (45)
Inqovi Myelodysplastic Syndrome	National Cancer Institute (NCI)	P1/2	CC (45)
dvx201 Myelodysplastic Syndrome	Coeptis Therapeutics	P1	CC (44)
Lyt-200 Myelodysplastic Syndrome	PureTech	P1	CC (44)
Magrolimab Myelodysplastic Syndrome	Novartis Pharmaceuticals	P2	CC (44)
Rivogenlecleucel Myelodysplastic Syndrome	Fred Hutchinson Cancer Center	P2/3	CC (44)
3d189 Myelodysplastic Syndrome	3D Medicines	P1	CC (43)
Anti-Pr1/Hla-A2 Monoclonal Antibody Hu8F4 Myelodysplastic Syndrome	M.D. Anderson Cancer Center	P1	CC (43)
Atezolizumab Myelodysplastic Syndrome	University of Southern California	P1/2	CC (43)
Atrn-119 Myelodysplastic Syndrome	Washington University School of Medicine	P1	CC (43)
Bisantrene Dihydrochloride Myelodysplastic Syndrome	Racura Oncology Ltd	P1	CC (43)
Calaspargase Pegol Myelodysplastic Syndrome	Andrew E. Place, MD	P1	CC (43)
Cbx-250 Myelodysplastic Syndrome	Crossbow Therapeutics, Inc.	P1	CC (43)
cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr Myelodysplastic Syndrome	Fred Hutchinson Cancer Center	P1	CC (43)
Cln-049 Myelodysplastic Syndrome	Cullinan Therapeutics Inc.	P1	CC (43)
Cytokine-Treated Veto Cells Myelodysplastic Syndrome	M.D. Anderson Cancer Center	P1/2	CC (43)
Hpc-A Myelodysplastic Syndrome	St. Jude Children's Research Hospital	P2	CC (43)
Icp-248 Myelodysplastic Syndrome	Beijing InnoCare Pharma Tech Co., Ltd.	P1	CC (43)
Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Cd47 (Cd47 Molecule, Integrin Associated Protein, Iap, Mer6, Oa3)] And Anti-[Homo Sapiens Cd274 (Programmed Cell Death 1 Ligand 1, Pdl1, Pd-L1, B7 Homolog 1, B7H1, B7-H1, Pdcd1Lg1)], Humanized Monoclonal Antibody, Bispecific, Bivalent Myelodysplastic Syndrome	Mabwell (Shanghai) Bioscience Co., Ltd.	P1/2	CC (43)
Jnj-89853413 Myelodysplastic Syndrome	Janssen Research & Development, LLC	P1	CC (43)
Jnj-90189892 Myelodysplastic Syndrome	Janssen Research & Development, LLC	P1	CC (43)
LY 3410738 Myelodysplastic Syndrome	Eli Lilly and Company	P1	CC (43)
Max-40279-01 Myelodysplastic Syndrome	Maxinovel Pty., Ltd.	P1/2	CC (43)
Mgta-117 Myelodysplastic Syndrome	Magenta Therapeutics, Inc.	P1	CC (43)
q702 Myelodysplastic Syndrome	Mayo Clinic	P1	CC (43)
Ratg Myelodysplastic Syndrome	Memorial Sloan Kettering Cancer Center	P2	CC (43)
Regorafenib Myelodysplastic Syndrome	City of Hope Medical Center	P1	CC (43)
Romiplostim Myelodysplastic Syndrome	First Affiliated Hospital of Zhejiang University	P1	CC (43)
Succimer Myelodysplastic Syndrome	M.D. Anderson Cancer Center	P1	CC (43)
Tak-243 Myelodysplastic Syndrome	National Cancer Institute (NCI)	P1	CC (43)
Tcr Transduced T-Cells Myelodysplastic Syndrome	National Cancer Institute (NCI)	P1	CC (43)
TQB3455 Myelodysplastic Syndrome	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P1	CC (43)
Uproleselan Myelodysplastic Syndrome	National Cancer Institute (NCI)	P1	CC (43)
vip943 Myelodysplastic Syndrome	Vincerx Pharma, Inc.	P1	CC (43)
Bpx-501 T Cells Myelodysplastic Syndrome	Bellicum Pharmaceuticals	P1/2	CC (42)
Navitoclax Myelodysplastic Syndrome	Thomas Jefferson University	P1	CC (42)
Abd-3001 Myelodysplastic Syndrome	Advanced BioDesign	P1/2	CC (41)
Anti-Clever-1 Monoclonal Antibody Fp-1305 Myelodysplastic Syndrome	Faron Pharmaceuticals Ltd	P1/2	CC (41)
cd70-targeting car-t cells Myelodysplastic Syndrome	St. Jude Children's Research Hospital	P1	CC (41)
cg009301 for Myelodysplastic Syndrome	Cullgen (Shanghai),Inc	P1	CC (41)
Ctx-712 Myelodysplastic Syndrome	Chordia Therapeutics, Inc.	P1/2	CC (41)
Dordaviprone Myelodysplastic Syndrome	University of Nebraska	P1/2	CC (41)
Eganelisib Myelodysplastic Syndrome	Stelexis BioSciences	P1	CC (41)
Enzomenib Myelodysplastic Syndrome	Sumitomo Pharma America, Inc.	P1/2	CC (41)
Ex-Vivo Expanded Γδ T Cell Infusion Myelodysplastic Syndrome	Chinese PLA General Hospital	P1/2	CC (41)
imm01 Myelodysplastic Syndrome	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	P1/2	CC (41)
Mobinitinib Myelodysplastic Syndrome	Ellipses Pharma	P1/2	CC (41)

Showing 151 to 200 of 296 assets

PreviousPage 4 of 6Next